Cepheid downgraded to Neutral from Overweight at Piper Jaffray Piper Jaffray downgraded Cepheid on concerns the company's Q4 results and FY13 outlook could miss expectations. The firm lowered its price target for shares to $34 from $42.
Cepheid to collaborate with FIND and Rutgers for novel tuberculosis test Cepheid, FIND, and Rutgers New Jersey Medical School, will collaborate to develop Xpert MTB/RIF Ultra, a next-generation test for Mycobacterium tuberculosis with increased sensitivity to aid in detection of patients with smear-negative TB, which is often associated with HIV co-infection. The collaboration is also receiving additional support from the National Institute of Allergy and Infectious Diseases at the NIH. Xpert MTB/RIF Ultra is expected to be available to the HBDC market in 1H16.